Highlights Orphazyme A/S

Equities

ORPHA

DK0062502894

Delayed Nasdaq Copenhagen Other stock markets 06:47:45 2024-04-29 am EDT			5-day change	1st Jan Change
1,090 ^DKK	0.00%		+8.46%	-18.05%

Mar. 27	Orphazyme A/S Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 04	FDA Extends Review of Zevra's Arimoclomol by Three Months	DJ

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Orphazyme A/S Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
FDA Extends Review of Zevra's Arimoclomol by Three Months	Mar. 04	DJ
Orphazyme A/S acquired an additional unknown minority stake in CombiGene AB (OM:COMBI).	Feb. 20	CI
Zevra Therapeutics Refiles Arimoclomol Application With FDA	Dec. 27	DJ
Orphazyme A/S Provides Earnings Guidance for the Full Year 2023	23-09-12	CI
Orphazyme A/S Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-12	CI
Orphazyme A/S Provides Earnings Guidance for the Full-Year 2023	23-05-30	CI
Orphazyme A/S Provides Earnings Guidance for the Full-Year 2023	23-04-25	CI
Orphazyme A/S Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-25	CI
Orphazyme A/S Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-26	CI
Orphazyme A/S Revises Earnings Guidance for the Year 2022	22-09-25	CI
Orphazyme A/S Reports Earnings Results for the Full Year Ended December 31, 2021	22-06-07	CI
Orphazyme A/S Provides Earnings Guidance for the Full Year of 2022	22-06-07	CI
Orphazyme Closes $18 Million Sale Of Assets, Business Operations Under Restructuring Plan	22-06-01	MT
KemPharm Denmark A/S acquired Substantially All Assets and Business Activities of Orphazyme A/S for $18 million.	22-05-30	CI
KemPharm Agrees to Buy Orphazyme for $12.8 Million	22-05-16	MT
KemPharm Denmark A/S agreed to acquire substantially all assets and business activities of Orphazyme A/S for $18 million.	22-05-14	CI
Orphazyme A/S Announces Withdrawal of European Marketing Authorisation Application for Arimoclomol for Treatment of Niemann-Pick Disease Type C	22-03-22	CI
Orphazyme to Halve Workforce to Cut Costs, to Delist from Nasdaq -- Stock Dives 40% After-Hours	22-03-10	MT
Orphazyme A/S Announces Update on Regulatory Review of Arimoclomol in the European Union	22-02-23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Orphazyme A/S

Equities

ORPHA

DK0062502894

Highlights

Filters